- Home
- CRBU vs KUKE Comparison
CRBU vs KUKE Comparison
Compare CRBU & KUKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBU
- KUKE
- Stock Information
- Founded
- CRBU 2011
- KUKE 2002
- Country
- CRBU United States
- KUKE China
- Employees
- CRBU N/A
- KUKE N/A
- Industry
- CRBU Medicinal Chemicals and Botanical Products
- KUKE Other Consumer Services
- Sector
- CRBU Health Care
- KUKE Real Estate
- Exchange
- CRBU Nasdaq
- KUKE Nasdaq
- Market Cap
- CRBU 93.0M
- KUKE 86.8M
- IPO Year
- CRBU 2021
- KUKE 2021
- Fundamental
- Price
- CRBU $1.63
- KUKE $3.03
- Analyst Decision
- CRBU Strong Buy
- KUKE
- Analyst Count
- CRBU 4
- KUKE 0
- Target Price
- CRBU $8.50
- KUKE N/A
- AVG Volume (30 Days)
- CRBU 1.9M
- KUKE 11.7K
- Earning Date
- CRBU 08-05-2025
- KUKE 07-31-2025
- Dividend Yield
- CRBU N/A
- KUKE N/A
- EPS Growth
- CRBU N/A
- KUKE N/A
- EPS
- CRBU N/A
- KUKE N/A
- Revenue
- CRBU $9,918,000.00
- KUKE $9,442,397.00
- Revenue This Year
- CRBU $9.52
- KUKE N/A
- Revenue Next Year
- CRBU N/A
- KUKE N/A
- P/E Ratio
- CRBU N/A
- KUKE N/A
- Revenue Growth
- CRBU N/A
- KUKE N/A
- 52 Week Low
- CRBU $0.66
- KUKE $1.45
- 52 Week High
- CRBU $3.00
- KUKE $17.50
- Technical
- Relative Strength Index (RSI)
- CRBU 66.57
- KUKE 46.33
- Support Level
- CRBU $1.34
- KUKE $2.90
- Resistance Level
- CRBU $1.79
- KUKE $3.09
- Average True Range (ATR)
- CRBU 0.12
- KUKE 0.12
- MACD
- CRBU 0.03
- KUKE 0.03
- Stochastic Oscillator
- CRBU 72.84
- KUKE 62.50
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
About KUKE Kuke Music Holding Limited
Kuke Music Holding Ltd provides classical music licensing, subscription, and education services in China. The company licenses its music content to online music entertainment platforms, such as Tencent Music Entertainment Group, digital music service providers, such as NetEase Cloud Music, as well as film and TV production companies, airlines, and smart hardware companies. Users can access the platform through the website, mobile app, and smart music devices.